Takeda Set To Appeal Latest $2m Actos Ruling
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical Co. Ltd. is expected to challenge the latest jury verdict in ongoing U.S. litigation surrounding its former blockbuster diabetes drug Actos (pioglitazone), in which the plaintiff was awarded around $2 million in compensatory damages.